GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eledon Pharmaceuticals Inc (FRA:2TK) » Definitions » Policy Acquisition Expense

Eledon Pharmaceuticals (FRA:2TK) Policy Acquisition Expense


View and export this data going back to 2014. Start your Free Trial

What is Eledon Pharmaceuticals Policy Acquisition Expense?

Policy Acquisition Expense only applies to insurance companies.


Eledon Pharmaceuticals Business Description

Traded in Other Exchanges
Address
19800 MacArthur Boulevard, Suite 250, Irvine, CA, USA, 92612
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.